What can we learn from real world studies on direct oral anticoagulants?
作者信息
Coppens M
机构信息
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
出版信息
Neth Heart J. 2017 Oct;25(10):545-550. doi: 10.1007/s12471-017-1029-5. Epub 2017 Aug 3.
Abstract
摘要
相似文献
1
What can we learn from real world studies on direct oral anticoagulants?我们能从直接口服抗凝剂的真实世界研究中学到什么？
Neth Heart J. 2017 Oct;25(10):545-550. doi: 10.1007/s12471-017-1029-5. Epub 2017 Aug 3.
2
To learn or not to learn from real-world experience on direct oral anticoagulants in pediatric patients?是否要从儿科患者直接口服抗凝剂的真实世界经验中学习？
Res Pract Thromb Haemost. 2023 Feb 15;7(1):100034. doi: 10.1016/j.rpth.2022.100034. eCollection 2023 Jan.
3
Direct Oral Anticoagulants in the Real World: Insights Into Appropriate Prescribing and Medication Use.现实世界中的直接口服抗凝剂：关于合理处方和药物使用的见解。
Can J Nurs Res. 2017 Sep;49(3):105-107. doi: 10.1177/0844562117716852. Epub 2017 Jul 5.
4
Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.真实世界中接受直接口服抗凝剂治疗的非瓣膜性心房颤动患者主要出血风险的比较：一项网状Meta分析。
Curr Med Res Opin. 2018 Mar;34(3):487-498. doi: 10.1080/03007995.2017.1411793. Epub 2017 Dec 8.
5
A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.一项单中心回顾性队列研究：比较低分子肝素与直接口服抗凝剂治疗癌症患者静脉血栓栓塞症——真实世界经验
J Oncol Pharm Pract. 2019 Jun;25(4):793-800. doi: 10.1177/1078155218757856. Epub 2018 Feb 20.
6
Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.直接作用口服抗凝剂与维生素K拮抗剂在非瓣膜性心房颤动中的安全性和有效性——基于真实世界数据的网状荟萃分析
Vasa. 2019 Mar;48(2):134-147. doi: 10.1024/0301-1526/a000746. Epub 2018 Nov 5.
7
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.比较直接口服抗凝剂与华法林用于心房颤动、静脉血栓栓塞和机械心脏瓣膜的情况。
Consult Pharm. 2015 Nov;30(11):644-56. doi: 10.4140/TCP.n.2015.644.
8
Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management.真实世界临床实践中直接口服抗凝剂的安全性：将临床试验转化为日常临床管理。
Expert Opin Drug Saf. 2019 Mar;18(3):187-209. doi: 10.1080/14740338.2019.1578344. Epub 2019 Feb 18.
9
Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the "Real World".“真实世界”中房颤患者的胃肠道出血与直接口服抗凝剂
Gastroenterology. 2017 Apr;152(5):932-934. doi: 10.1053/j.gastro.2017.02.027. Epub 2017 Mar 1.
10
Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.非瓣膜性心房颤动初治患者中直接口服抗凝剂（DOACs）的真实世界持久性。
Int J Cardiol. 2019 Aug 1;288:72-75. doi: 10.1016/j.ijcard.2019.04.061. Epub 2019 Apr 19.
引用本文的文献
1
Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network.意大利直接口服抗凝剂五年使用情况：来自意大利国家药物警戒网络的药物不良反应
J Clin Med. 2022 Jun 4;11(11):3207. doi: 10.3390/jcm11113207.
本文引用的文献
1
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.利伐沙班在荷兰的实际应用：来自“Xarelto用于预防房颤患者中风”（XANTUS）注册研究的数据。
Neth Heart J. 2017 Oct;25(10):551-558. doi: 10.1007/s12471-017-1009-9.
2
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
3
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较：随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
4
Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based.接受维生素K拮抗剂治疗的患者出现出血情况，而这些患者原本会被排除在确定抗凝适应症的试验之外。
Blood. 2008 May 1;111(9):4471-6. doi: 10.1182/blood-2007-11-123711. Epub 2008 Mar 3.
Zotero 插件